Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Investor Day (June 2021)
69 slides from Fisher & Paykel Healthcare's investor day presentation, Jun 1, 2021
Slide 1: News Release: Investor Series presentations
News Release STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) Fisher & Paykel Healthcare provides Investor Series presentations For personal use only Auckland, New Zealand, 1 June 2021 - Fisher & Paykel Healthcare Corporation Limited attaches a copy of its presentations to analysts and in
Slide 2: Welcome to the Fisher & Paykel Healthcare Virtual Investor Series
For personal use only Welcome to the Welcome to the Fisher & Paykel Fisher & Paykel Healthcare Healthcare Virtual Investor Series Virtual Investor Series Andrew Somervell – Vice President Products and Technology Andrew Somervell – Vice President Products and Technology
Slide 3: Our purpose
Our purpose For personal use only Improving care & outcomes through inspired and world-leading healthcare solutions
Slide 4: Our strategy
Our strategy For personal use only We aim to grow our business in a way that is sustainable over the long term by creating better products, extending our global reach and changing clinical practice.
Slide 5: Our aspiration
Our aspiration For personal use only We’ve established an enviable track record for delivering SUSTAINABLE REVENUE GROWTH.
Slide 6: Hospital respiratory support: short-term growth
Hospital respiratory support For personal use only Where will sustainable growth come from in the SHORT-TERM?
Slide 7: Home respiratory support: medium-term growth
Home respiratory support For personal use only Where will sustainable growth come from in the MEDIUM-TERM?
Slide 8: Surgical technologies: longer-term growth
Surgical technologies For personal use only Where will sustainable growth come from in the LONGER-TERM?
Slide 9: Our aspiration: doubling revenue every 5-6 years
Our aspiration For personal use only OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years. *CONSTANT CURRENCY
Slide 10: Our strategy
Our strategy For personal use only OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare solutions
Slide 11: A patient centred approach
A patient centred approach For personal use only Patient Care is Complex Doing the right thing for our patients All parties want the best outcome for patients Complexity provides opportunity Leads to long term thinking Deep understanding of patients and their care New Insight / Original Thought Valu
Slide 12: Virtual investor series itinerary
Virtual investor series itinerary For personal use only Day 1 – Changing clinical practice / Better products • Optiflow: Hospital Respiratory Support – Sam Frame Day 2 – Changing clinical practice / Better products • Optiflow: Home Respiratory Support – Rob Kirton • Surgical – Winston Fong (VP Surgi
Slide 13: Optiflow Nasal High Flow therapy
For personal use only Optiflow™ Nasal High Flow therapy Sam Frame Marketing Manager – Optiflow and Airvo
Slide 14: Hospital Respiratory Support
Hospital Respiratory Support For personal use only OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare solutions
Slide 15: Changing clinical practice is difficult
Changing Clinical Practice For personal use only Changing clinical practice is difficult OUR PURPOSE Improving care & Global practice change outcomes through inspired and world- leading healthcare solutions Local practice change
Slide 16: Global Practice Change
Global Practice Change For personal use only Guideline Systematic review with meta-analysis Systematic review Clinical outcome controlled trial Physiological/Pilot controlled trial Observational study/Cohort study Case report/Case series Editorial/Commentary/Opinion/Narrative Benchtop/descriptive st
Slide 17: Global Practice Change: NHF publications in adults
Global Practice Change Publications featuring NHF for respiratory support in Adults For personal use only Critical review Guideline Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiological/Pilot controlled trial Obs
Slide 18: Global Practice Change: NHF publications in adults
Global Practice Change Publications featuring NHF for respiratory support in Adults For personal use only Critical review Guideline Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiological/Pilot controlled trial Obs
Slide 19: Global Practice Change: NHF publications in adults
Global Practice Change Publications featuring NHF for respiratory support in Adults For personal use only Critical review Guideline Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiological/Pilot controlled trial Obs
Slide 20: Local Practice Change
Local Practice Change For personal use only Requires us to change practice hospital by hospital
Slide 21: Changing Clinical Practice
Changing Clinical Practice For personal use only Changing clinical practice is difficult Global practice GLOBAL LOCAL change helps local PRACTICE PRACTICE CHANGE CHANGE Local practice change helps global
Slide 22: Better products: Optiflow systems
Better products For personal use only Optiflow systems Applying our expertise OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare Broad application solutions Adoption
Slide 23: Airvo Optiflow System
Airvo Optiflow System For personal use only
Slide 24: Humidification
For personal use only Humidification
Slide 25: Broad application
For personal use only Broad application
Slide 26: Adoption
Adoption Publications featuring NHF for respiratory support in Adults For personal use only Critical review Guideline Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiological/Pilot controlled trial Observational stu
Slide 27: Adoption
Adoption Publications featuring NHF for respiratory support in Adults For personal use only Critical review Guideline Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiological/Pilot controlled trial Observational stu
Slide 28: Broad application
For personal use only Broad application
Slide 29: Broad application
For personal use only Broad application
Slide 30: Hospital Respiratory Support
Hospital Respiratory Support For personal use only OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare solutions
Slide 31: Home Respiratory Support - myAirvo
Home Respiratory For personal use only Support -myAirvo Dr Robert Kirton Marketing Manager
Slide 32: myAirvo
myAirvo • Better patient outcomes For personal use only • Reduce chronic patients hospital • Major cost of care • Initial target COPD
Slide 33: myAirvo - Care Continuum
myAirvo - Care Continuum • Chronic patient has respiratory For personal use only exacerbation Hospital • Treated with AIRVO/Optiflow in hospital • Discharged from Hospital • Prescribed myAirvo for home use
Slide 34: myAirvo - Nasal High Flow Therapy
myAirvo - Nasal High Flow Therapy • Humidified air for respiratory For personal use only support − Body temperature and 100% Humidified • Essential for therapy tolerance • Essential for improving mucus clearance − 2 to 60 l/min of gas flow • Making breathing easier • Wash out CO2 • If oxygen require
Slide 35: myAirvo – Who uses it?
myAirvo – Who uses it? For personal use only Anyone with a Chronic Respiratory Disease Other respiratory Initial focus is COPD conditions • 3rd leading chronic killer (WHO) • Bronchiectasis • Asthma • 6-8% of the population • Cystic Fibrosis • Estimates ~ 384 M people worldwide • ILD / IPF • Limited
Slide 36: COPD – Chronic Obstructive Pulmonary Disease
COPD – Chronic Obstructive Pulmonary Disease For personal use only Debilitating and incurable Progressive disease Can slow progression and improve quality of life Reduce exacerbations and going to hospital “COPD is like ‘spending ten years drowning,’ to quote one of my patients’ progressive dyspnea
Slide 37: GOLD characterisation of COPD
GOLD characterisation of COPD • Global Strategy for the Diagnosis, For personal use only FEV1 Management, and Prevention of % predicted COPD Gold 1 ≥80 • Degree of COPD is characterized by the airflow limitation Gold 2 50-79 (obstructive) − “How hard to breath in and out” − As disease progresses, ge
Slide 38: GOLD characterisation of COPD
GOLD characterisation of COPD • Global Strategy for the Diagnosis, For personal use only Management, and Prevention of COPD C D Increasing exacerbations • Degree of COPD is characterized by the airflow limitation (obstructive) − “How hard to breath in and out” − As disease progresses, get harder A B
Slide 39: COPD: Key Published Clinical Evidence
COPD: Key Published Clinical Evidence For personal use only
Slide 40: Quality of Clinical Evidence
Quality of Clinical Evidence For personal use only Establish causality bias GUIDELINES: Clinical practice guideline, review of systematic reviews with recommendations. Guidelines Systematic review with meta-analysis SYSTEMATIC REVIEWS: e.g. Cochrane Collaboration Review Synthesizes and critically an
Slide 41: Quality of Clinical Evidence
Quality of Clinical Evidence For personal use only Establish causality bias GUIDELINES: Clinical practice guideline, review of systematic reviews with recommendations. Guidelines Systematic review with meta-analysis Optiflow systems including Airvo SYSTEMATIC REVIEWS: e.g. Cochrane Collaboration Rev
Slide 42: Quality of Clinical Evidence: Unstable Higher Acuity
Quality of Clinical Evidence Unstable Higher Acuity Publications featuring NHF for respiratory support in adults For personal use only Critical review Guidelines Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiologi
Slide 43: Quality of Clinical Evidence: Unstable Higher Acuity
Quality of Clinical Evidence Unstable Higher Acuity Publications featuring NHF for respiratory support in adults For personal use only Critical review Guidelines Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiologi
Slide 44: Quality of Clinical Evidence: Stable Low Acuity
Quality of Clinical Evidence Stable Low Acuity Publications featuring NHF for respiratory support in stable adults For personal use only Critical review Guidelines Systematic review with meta-analysis Interventional Systematic review Guideline Clinical outcome controlled trial Observational Physiolo
Slide 45: myAirvo – Growing Clinical evidence
myAirvo – Growing Clinical evidence For personal use only Many studies underway to Early evidence strengthen clinical very promising evidence COPD studies = 13 Pulmonary rehab studies = 5 (COPD) = 5 (other diseases) Needs to change Other disease studies = 5 clinical practice
Slide 46: Summary
Summary • Many potential patients for For personal use only myAirvo in the home • COPD a major market opportunity with largely unmet need • Growing clinical evidence • Changing clinical practice
Slide 47: Surgical Humidification
Surgical For personal use only Humidification Winston Fong VP Surgical Technologies
Slide 48: Intro – Laparoscopy and laparotomy
Intro – Laparoscopy and laparotomy For personal use only 14M 6M Laparoscopy Laparotomy procedures procedures 1 2 1. https://www.thestar.com.my/lifestyle/health/2017/05/07/a-keyhole-to-health; 2. Sugarbaker PH. Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface m
Slide 49: Cold dry exposure to the patient
Cold dry exposure to the patient For personal use only • Patient is exposed to cold and dry CO2 (laparoscopy) or ambient air (laparotomy) during surgery • Very different to natural physiological state (warm and wet) • Cold and dry CO2 causes evaporation which results in loss of heat and moisture fro
Slide 50: What's the impact from cold dry exposure?
What’s the impact from cold dry exposure? CONTROL COLD, DRY For personal use only Hypothermia Evaporative heat loss due to exposure to cold, dry CO2 and/or cold, dry operating room environment AT THE START OF INSUFFLATION AFTER 2 HOURS OF INSUFFLATION Tissue/Cell damage Effect of cold, dry CO2 and/o
Slide 51: Implications of Hypothermia and Tissue/Cell damage
Implications of Hypothermia and Tissue/Cell damage Intraoperative Postoperative For personal use only Hypothermia Surgical site infection Adhesions Peritoneal Tumor Metastasis Tissue / Cell damage
Slide 52: Surgical Humidification with HumiGard
Surgical Humidification with HumiGard For personal use only • Surgical Humidification Platform − Tuned to deliver warm humidified CO2 • Humidified Consumables Kit − Thermally insulated tube – prevents the loss of heat and humidity to the theatre environment − Optimised for Operating Room environment
Slide 53: Growing the clinical evidence
Growing the clinical evidence For personal use only Surgical Humidification research publications per annum 14 12 10 8 6 4 2 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Underway
Slide 54: Benefit of improved patient outcomes
Benefit of improved patient outcomes For personal use only Costs of Care in the Operating Room • 30% of hospital admissions are 38% through the Operating theatres. These admissions represent 50% 7% Medical Supplies of hospital costs Other direct • Cost of a hospital stay after a 9% Indirect (i.e. ho
Slide 55: Summary
Summary • Surgical humidification plays a key For personal use only part in establishing a third market within the hospital. • Right for the patient, good for the caregivers and hospital systems • ~20M patients (14M Lap, 6M Open) globally
Slide 56: Global Reach: Sales & Marketing
Global Reach For personal use only Sales & Marketing Justin Callahan - President North American Operations
Slide 57: Positioning: Value vs Cost
Positioning For personal use only Value vs Cost $8000 $7000 ~$8000 Value $6000 ~$6000 Cost benefit COPD average $5000 from reimbursement COPD average reduced $4000 Cost of stay cost of stay escalation $3000 $2000 $1000 F&P Optiflow Conventional Higher cost oxygen therapy therapy consumables
Slide 58: Changing Clinical Practice
Changing Clinical Practice Using clinical evidence to drive For personal use only change Multi layered with multiple stakeholders Insert image of products in action and Building confidence with usage inline or Sales talking with with the evidence, demonstrating clinician value Products in each care
Slide 59: Opportunity across the Care Continuum
Opportunity across the Care Continuum For personal use only ICU ED WARD HOME Invasive Ventilation Noninvasive OSA Ventilation Optiflow Nasal High Flow
Slide 60: Reach & Expertise
Reach & Expertise Acute Care Homecare For personal use only Focused Sales Team Focused Sales Team • Sales teams need to be experts in the • Developing strong collaborative clinical application across the care relationships with Key Opinion Leaders continuum • Manage complex supply chain • Utilize mu
Slide 61: Global reach in Developing Markets
Global reach For personal use only in Developing Markets Bryan Peterson - General Manager International Sales - ROW
Slide 62: Changing Clinical Practice: Evolution of a therapy
Changing Clinical Practice Evolution of a therapy to change clinical practice For personal use only − Therapy/Product Development • Ideas / observations • Improvements to therapy with existing technology • Refinement of ideas / development of prototypes, constant improvement • Clinical evaluation −
Slide 63: Our Global Coverage
Our Global Coverage For personal use only Our people are located in 45 countries Sell into more than 120+ countries With more than 180+ Distributors
Slide 64: The Market Development Curve
The Market Development Curve For personal use only
Slide 65: The Market Development Curve
The Market Development Curve For personal use only Developed Markets Developing Markets
Slide 66: Enhancing Distribution Partners
Enhancing Distribution Partners Distribution Partners For personal use only • Independent local company • Sales/Marketing team • Finance/Operations team • May distribute few or many products • Typically 10-100 people Multi-channel distribution • Focus • Training & support • Strategic alignment
Slide 67: Story remains the same
Story remains the same For personal use only • Changing Clinical Practice • Reducing escalation of care • Enhancing the de-escalation of care and avoidance of rebound • Sustainable sales
Slide 68: Lessons learned accelerates growth
Lessons learned accelerates growth For personal use only • Knowledge and learnings from the Developed markets drives growth in Developing markets Developed − Same patients Market − Same environment, − Potentially different resources available • Working with KOL’s, educating clinicians on therapy, su
Slide 69: Improving care and outcomes
Improving care and outcomes For personal use only People Helping People
Fisher & Paykel Healthcare — Investor Day (June 2021) on 6ix